Marc Wade Rosenbaum, chief accounting officer at iRhythm Holdings Inc, completed a sale of common stock on February 25, 2026, disposing of 4,797 shares at a per-share price of $135.4189. The total proceeds from that transaction are approximately $649,604.
The sale followed a separate transaction on February 24, 2026, in which Rosenbaum acquired 9,210 shares through the vesting of performance Restricted Stock Units that were originally granted on August 11, 2023. Those vested shares were recorded with a value of $0 and a unit price of $0.0 in the reporting.
After accounting for the February 24 vesting and the February 25 sale, Rosenbaum directly holds 15,014 shares of iRhythm common stock.
Market context provided alongside the filing notes that iRhythm's stock has slipped 12% over the past week and is trading roughly 34% below its 52-week high of $212, according to InvestingPro data. The company is assigned a market valuation of $4.52 billion and is characterized as overvalued based on InvestingPro's Fair Value analysis. For investors seeking additional depth, a Pro Research Report covering IRTC and more than 1,400 other U.S. equities is available.
Separately, iRhythm Technologies reported material operating results and guidance that point to momentum in the business. The company posted fourth-quarter revenue of $208.9 million, a year-over-year increase of 27.1% and about 4% above consensus estimates. Management attributed the quarter's revenue strength to the performance of ZioAT and progress with channel partners.
Notably, the company recorded positive GAAP net income for the period and delivered adjusted EBITDA of $34.3 million - marking the first time it has achieved a positive adjusted EBITDA figure. Looking ahead to 2026, iRhythm projected revenue growth of 17% to 18%, with an expected revenue range of $870 million to $880 million. The company also forecast an adjusted EBITDA margin in the neighborhood of 11.5% to 12.5% for the year.
Analyst coverage reacted to the quarterly updates and outlook with modest adjustments to valuations. Truist Securities and Canaccord Genuity lowered their price targets to $200 and $198, respectively, while maintaining Buy ratings. Morgan Stanley reiterated an Overweight rating with a $205 price target, citing the company's strong fourth-quarter results and record unit volume.
The combination of insider stock movement, updated financial results, and shifted analyst targets presents a mixed set of signals for investors monitoring iRhythm's trajectory. The internal transaction by the chief accounting officer - which includes both the vesting of performance RSUs and a subsequent open-market sale - is recorded alongside the company's growing revenue base and improved profitability metrics.